Biotech Astex Pharmaceuticals made a huge pop today, after RBC gave the stock an upgrade to “outperform,” calling it an “undiscovered gem” and raising the price target a whopping 40%. In this video, Motley Fool health-care analyst David Williamson tells investors about some potentially very exciting phase 2 data soon to be released by the company and gives us a picture of what it could mean for Astex if its trial data is as good as RBC thinks.

Can Celgene continue to soar?
Despite its exciting pipeline, Astex’s only marketed product at the moment is Dacogen, which is currently in direct competition with Celgene‘s Vidaza. Every in-the-know biotech investor has an eye on Celgene. Shares have skyrocketed this year as the company outlined a plan to almost triple its profits in only a few years. But should you buy the story Celgene is selling? Make sure you understand the key opportunities and risks facing this company by picking up The Motley Fool‘s brand-new premium report on Celgene. To claim your copy today, simply click here now.

var FoolAnalyticsData = FoolAnalyticsData || []; FoolAnalyticsData.push({ eventType: “TickerReportPitch”, contentByline: “David Williamson“, contentId: “cms.29629”, contentTickers: “NYSE:JNJ, NYSE:AZN, NASDAQ:CELG, NASDAQ:ASTX”, contentTitle: “Is This Biotech an Undiscovered Gem?”, hasVideo: “True”, pitchId: “128”, …read more
Source: FULL ARTICLE at DailyFinance